Results 151 to 160 of about 12,569 (203)

[ESBL – risk factors and treatment].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2016
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ESBLs: A Clear and Present Danger?

Critical Care Research and Practice, 2012
Extended spectrum β-lactamases (ESBLs) are enzymes produced by a variety of Gram negative bacteria which confer an increased resistance to commonly used antibiotics. They are a worrying global public health issue as infections caused by such enzyme-producing organisms are associated with a higher morbidity and mortality and greater fiscal burden ...
, Clark John
exaly   +2 more sources

Characterization of ESBL disseminating plasmids

Infectious Diseases, 2015
Bacteria producing extended-spectrum β-lactamases (ESBLs) constitute a globally increasing problem that contributes to treatment complications and elevated death rates. The extremely successful dissemination by ESBL-producing Enterobacteriaceae during the latest decades is a result of the combination of mobilization, evolution and horizontal spread of ...
Alma, Brolund, Linus, Sandegren
openaire   +2 more sources

Detection of extended-spectrum beta-lactamase (ESBL)-producing strains by the Etest ESBL screen

Journal of Clinical Microbiology, 1996
Resistance to contemporary broad-spectrum beta-lactams, mediated by extended-spectrum beta-lactamase (ESBL) enzymes, is an increasing problem worldwide. The Etest (AB Biodisk, Solna, Sweden) ESBL screen uses stable gradient technology to evaluate the MIC of ceftazidime alone compared with the MIC of ceftazidime with clavulanic acid (2 micrograms/ml) to
M G, Cormican, S A, Marshall, R N, Jones
openaire   +2 more sources

Cefepime pharmacodynamics in patients with extended spectrum β-lactamase (ESBL) and non-ESBL infections

Journal of Infection, 2007
This study was designed to compare cefepime exposures with microbiological outcomes in ESBL and non-ESBL infections and determine the pharmacodynamic profiles associated with successful outcome.Cefepime pharmacodynamic exposures of unbound drug [time above MIC (fT>MIC), minimal concentration over MIC (fC(min)/MIC), and area under the curve over MIC ...
Su Young, Lee, Joseph L, Kuti, David P, Nicolau   +2 more
openaire   +2 more sources

[Change of ESBLs-KPN and ESBLs-ECO after antimicrobial intervention].

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2011
To evaluate the change of extended spectrum beta-lactamase (ESBLs) Producing Klebsiella Pneumoniae (ESBLs-KPN) and Escherichia coli (ESBLs-ECO) causing nosocomial infection after antimicrobial intervention.We regularly monitored the data on the yearly consumption [defined as daily dose (DDD) per 1 000 patient-days] of frequently used antibiotics from ...
Yawen, Gao, Yu, Yang, Yuetao, Wu, Wei, Cao, Qiwei, Zhou   +4 more
openaire   +1 more source

Patiënt met ESBL

2017
Geachte mevrouw Abraham-Inpijn, u hebt aangeboden dat wij per mail vragen mogen stellen. Ik wil heel graag op uw aanbod terugkomen. Ik heb een patient in een verpleegkliniek. Hij komt min of meer regelmatig naar mijn praktijk voor onder andere gebitsreiniging.
openaire   +1 more source